3D intestinal model comprising adult stem cell-derived colon organoids grown as perfused epithelial tubules in stable co-culture with primary macrophages and fibroblasts embedded in ECM

Photo credit: Mimetas

Photo credit: Mimetas

The translation of biomedical knowledge to patients and users results in new medicines, medical technologies, and food products. This benefits our health, our environment, and economy. Animal testing is currently an important link in the biomedical development process, but it is increasingly under pressure. Often, animal tests are not a good model for human application; they are time-consuming, expensive, and cause animal suffering. To continue improving the health of humans and animals, a radically different approach is needed: making the step to humans and animals faster and more effective, without relying on animal testing by default.

The new Ombion Centre for Animal-Free Biomedical Translation (Ombion), formerly known as the CPBT, will shape this approach, creating new business opportunities around animal-free technologies and biomedical translation. This allows the Netherlands to distinguish itself globally and realize its ambition of becoming a leader in animal-free innovation.

Aim

Ombion is a national centre for valorizing and disseminating animal-free innovations and expertise. It aims to improve and accelerate the transition of new biomedical innovations to patients and users, at lower costs, and without the use of animals. This will lead to safer, more effective, and better medicines while reducing animal testing.

Together with a large number of national and international partners, Ombion will work on the development and dissemination of animal-free biomedical innovations and expertise. The initial transition projects will focus on ALS, cystic fibrosis, osteoarthritis/rheumatic diseases, and asthma/COPD. Ombion will implement the available and developed methods, tools, and expertise together with researchers and companies. The new centre will also offer education, training, advice, and support to enhance the acceptance and use of animal-free biomedical innovations. Combined, Ombion will run an integrated program that accelerates the transition to animal-free testing and strengthens the Dutch economy.

Budget

The total budget available to Ombion in the period from 2025 to 2034 is 245 million euros. 124.5 million of this budget is an investment from the Dutch National Growth Fund (NGF); the other funds are contributed by public and private Ombion partners.

The translation of biomedical knowledge to patients and users results in new medicines, medical technologies, and food products. This benefits our health, our environment, and economy. Animal testing is currently an important link in the biomedical development process, but it is increasingly under pressure. Often, animal tests are not a good model for human application; they are time-consuming, expensive, and cause animal suffering. To continue improving the health of humans and animals, a radically different approach is needed: making the step to humans and animals faster and more effective, without relying on animal testing by default.

The new Ombion Centre for Animal-Free Biomedical Translation will shape this approach, creating new business opportunities around animal-free technologies and biomedical translation. This allows the Netherlands to distinguish itself globally and realize its ambition of becoming a leader in animal-free innovation.

Aim

Ombion is a national centre for valorizing and disseminating animal-free innovations and expertise. It aims to improve and accelerate the transition of new biomedical innovations to patients and users, at lower costs, and without the use of animals. This will lead to safer, more effective, and better medicines while reducing animal testing.

Together with a large number of national and international partners, Ombion will work on the development and dissemination of animal-free biomedical innovations and expertise. The initial transition projects will focus on ALS, cystic fibrosis, osteoarthritis/rheumatic diseases, and asthma/COPD. Ombion will implement the available and developed methods, tools, and expertise together with researchers and companies. The new centre will also offer education, training, advice, and support to enhance the acceptance and use of animal-free biomedical innovations. Combined, Ombion will run an integrated program that accelerates the transition to animal-free testing and strengthens the Dutch economy.

Budget

The total budget available to Ombion in the period from 2025 to 2034 is 245 million euros. 124.5 million of this budget is an investment from the Dutch National Growth Fund (NGF); the other funds are contributed by public and private Ombion partners.

News

Heading

Help shape the future of regulators’ training on non-animal methodologies

Are you a regulator, risk assessor, or risk manager working with pharma, chemicals, biotech, medical devices, toxicology, food or environmental safety? Please share your view. Your input will guide the development of tomorrow’s training for regulatory professionals.

Your insights will directly support the Global Education Hub and the Ombion Centre for Animal-Free Biomedical Translation (CPBT) in co-creating practical, forward-looking, ad hoc training tools.

Take the survey now! It only takes about 10 minutes to complete and is completely anonymous. The survey is open until 31 October 2025.

Ombion celebrates launch and site opening

On 7 July 2025, the Centre for Animal-free Biomedical Translation, supported by the Dutch National Growth Fund, was officially launched under its new name: Ombion Centre for Animal-free Biomedical Translation. Read more

Press release on CPBT funding

The press release on the NGF investment in CPBT was published on the Utrecht University website and many CPBT partner websites. It was also shared by various external media channels. Read the press release here

ARD Tagesthemen television broadcast

German Public television channel ARD broadcasted an item showcasing examples of animal-free research and educational alternatives recorded at Utrecht University. View the broadcast on LinkedIn here (in German)

BNR Nieuwsradio podcast episode

BNR Nieuwsradio show 'Wetenschap Vandaag' created a podcast episode on the CPBT. Wouter Dhert (UU), Anne Kienhuis (RIVM) and Jeffrey Beekman (UMC Utrecht) were interviewed about CPBT and their research. Listen to the podcast here (in Dutch)

Ombion at Utrecht Science Park

Ombion will be established as a physical centre located at Utrecht Science Park, where expertise and infrastructure from leading Dutch knowledge institutions, research centres, and businesses come together to drive the transition to animal-free innovation. Ombion will serve as a one-stop shop for organisations interested in adopting animal-free biomedical translation or for those looking to conduct preclinical research in the most efficient way. Our approach is built on four interconnected components explained below, forming a comprehensive strategy to enhance biomedical research and translation. The centre will leverage the knowledge and tools developed through its transition projects, transforming them into marketable propositions and spin-outs, supported by in-house expertise.

How Ombion operates

Transition Projects: Within Ombion's transition projects, public and private partners will collaborate to develop new tools, methods, and knowledge to demonstrate the transition to animal-free biomedical translation in light of current biomedical challenges. The initial transition projects focus on ALS, Cystic Fibrosis, Osteoarthritis & Rheumatoid Arthritis, and Asthma & COPD.

Expertise Development: Alongside the transition projects, Ombion will implement an in-house advanced development program. This program will expand the knowledge acquired from the transition projects and cultivate new expertise, thereby strengthening each proposition and addressing existing challenges and hurdles. The Ombion's efforts will concentrate on four key areas:

  1. Transition science, ethics, and sustainability
  2. Regulatory innovation
  3. Educational program development
  4. Data science, supporting tools and models

Propositions: The methods, tools, and expertise developed within the transition projects are used to create propositions for academic researchers, companies, and governmental bodies. Ombion will provide the following propositions:

  1. Training and education on animal-free biomedical translation
  2. Advising on existing data, tools and methods for animal-free biomedical translation
  3. Providing support for the validation and adoption of animal-free tools and models
  4. Supporting the development of new animal-free methods, tools, and models.

Spin-out Activities: Ombion will support spin-outs emerging from the new products, methods, tools, expertise, and services developed within its transition projects. This support will include mobilising financing, drafting business plans, building strong teams, and integrating these spin-outs into the thriving animal-free innovation ecosystem.

Ombion at Utrecht Science Park

Ombion will be established as a physical centre located at Utrecht Science Park, where expertise and infrastructure from leading Dutch knowledge institutions, research centres, and businesses come together to drive the transition to animal-free innovation. Ombion will serve as a one-stop shop for organisations interested in adopting animal-free biomedical translation or for those looking to conduct preclinical research in the most efficient way. Our approach is built on four interconnected components explained below, forming a comprehensive strategy to enhance biomedical research and translation. The centre will leverage the knowledge and tools developed through its transition projects, transforming them into marketable propositions and spin-outs, supported by in-house expertise.

How Ombion operates

Transition Projects: Within Ombion's transition projects, public and private partners will collaborate to develop new tools, methods, and knowledge to demonstrate the transition to animal-free biomedical translation in light of current biomedical challenges. The initial transition projects focus on ALS, Cystic Fibrosis, Osteoarthritis & Rheumatoid Arthritis, and Asthma & COPD.

Expertise Development: Alongside the transition projects, Ombion will implement an in-house advanced development program. This program will expand the knowledge acquired from the transition projects and cultivate new expertise, thereby strengthening each proposition and addressing existing challenges and hurdles. Ombion's efforts will concentrate on four key areas:

  1. Transition science, ethics, and sustainability
  2. Regulatory innovation
  3. Educational program development
  4. Data science, supporting tools and models

Propositions: The methods, tools, and expertise developed within the transition projects are used to create propositions for academic researchers, companies, and governmental bodies. Ombion will provide the following propositions:

  1. Training and education on animal-free biomedical translation
  2. Advising on animal-free biomedical translation
  3. Providing support for the validation and adoption of animal-free tools and models
  4. Supporting the development of new animal-free methods, tools, and models.

Spin-out Activities: Ombion will support spin-outs emerging from the new products, methods, tools, expertise, and services developed within its transition projects. This support will include mobilising financing, drafting business plans, building strong teams, and integrating these spin-outs into the thriving animal-free innovation ecosystem.

Our partnership

At Ombion, a diverse consortium of academic scientists, lecturers and researchers from universities of applied sciences, industry partners, regulatory agencies, patient organizations, government bodies, and NGOs will collaborate to pave the way for more accurate and cost-effective medicines, minimizing the need for animal testing.

Core partners:
Utrecht University, HU University of Applied Sciences Utrecht, UMC Utrecht.

The Ombion Centre for Animal-free Biomedical Translation National Growth Fund application was submitted by the Ministry of Agriculture, Fisheries, Food Security and Nature (LVVN, formerly LNV) within the framework of its Transitie Proefdiervrije Innovatie (TPI) program.

Ombion partners (in alphabetical order):
3BrainAG, Allegro, ALS patiëntenvereniging, Amsterdam University Medical Center (AUMC), Aquilo, ArthroSave, Aryzon, AstraZeneca, Azar innovations, Chondropeptix, CHRN on-chip biotechnologies B.V, Citeq, Danone Nutricia Research, Eindhoven University of Technology (TU/e), Elevate Academy, Erasmus MC, ETB-bislife, EU JRC (EU Joint Research Centre, JRC), EU Reference Laboratory for alternatives to animal testing (JRC-ECVAM), FAIR Therapeutics, Genmab, GQ Bio Therapeutics, hDMT, hiPSC hotel LUMC, HIT CF Europe, HU University of Applied Sciences Utrecht, Humane Society International (HSI), InnoCore Pharmaceuticals, intoSURGERY, Johns Hopkins Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Leiden University Medical Center (LUMC), Liposphere, Longfonds, Maastricht Universiteit (MU), Medicines Evaluation Board (CBG), Mimetas, National Institute for Public Health and the Environment (RIVM), NCFS, NeoVentures Biotechnology Europe, Netri, NLC, Nordic Bioscience, Optics11 Life, Orthros Medical, QurAlis, Radboud University (RU), Radboudumc, Recode Therapeutics, ReumaNederland, Roche, Sanofi, Stichting ALS Nederland, Stichting Proefdiervrij, Synapticure, Tecan, TNO, Treeway, UMC Utrecht, Unilever, University Medical Center Groningen (UMCG), University of Groningen (RUG), Utrecht University, VectorY, Wageningen University & Research (WUR), ZEISS & Arivis, ZonMw

Vacancy: Project Manager

Location: Utrecht Science Park, The Netherlands (hybrid 50/50) 
Organisation: Ombion Centre for Animal-Free Biomedical Translation 
Employment Type: Full-time 
Seniority Level: Medior

About Ombion Centre for Animal-Free Biomedical Translation

The Netherlands is poised to lead the transition to animal-free biomedical innovation by establishing the Ombion Centre for Animal-Free Biomedical Translation (Ombion). Ombion’s goal is to improve the biomedical translation processes while making them animal-free. This will accelerate the development of new medicines, medical devices and food ingredients that enhance human health, by replacing animal testing, which is often inaccurate and costly. This process is long, expensive, and high-risk, with animal testing traditionally used to predict efficacy and safety for humans. However, animal experiments often fail to provide accurate predictions, leading to substantial investments in clinical testing for products that ultimately do not succeed, while also causing animal suffering. Despite these shortcomings, the use of animal testing remains widespread due to several key factors: (i) animal testing is still regarded as the “gold standard”, (ii) many alternatives have not yet been validated and/or accepted, (iii) developing alternative methods requires large investments, with uncertain returns, and (iv) there is a lack of strong leadership to drive change in this polarized field. Ombion is a national centre, with a unique infrastructure at Utrecht Science Park – for developing and valorising animal-free innovations and expertise. Ombion operates through four key pillars: 

  • Transition projects to prove that the transition to animal-free biomedical translation is effective and feasible, and to develop knowledge and methods; 
  • Propositions to advise, train and assist stakeholders in making the transition and adopting animal-free methods; 
  • Additional expertise development to strengthen the propositions; 
  • Spin-out activities to create business opportunities that commercialize biomedical innovations and solutions for animal-free translation internationally. 

Ombion is a forward-thinking organisation committed to innovation, collaboration, and excellence. We foster a culture of inclusivity, continuous learning, and impact-driven work. Our team is composed of passionate professionals who strive to make a difference through strategic projects and partnerships.

About the role

Are you a dynamic and detail-oriented professional with a passion for project management and stakeholder collaboration? Ombion is seeking an experienced Project Manager to join our team and play a pivotal role in driving strategic initiatives, managing reporting processes, and coordinating with internal and external partners. This is an exciting opportunity to contribute to impactful projects in a fast-paced and innovative environment.

Key Responsibilities

  • Coordinate and compile financial and content-based reporting, including RVO reporting requirements.
  • Engage with project managers across decentralized teams to gather and consolidate project data.
  • Support contract management processes with private partners, ensuring compliance and timely execution.
  • Collaborate with location managers to organize and manage laboratory operations and logistics.
  • Ensure timely and accurate documentation of project milestones, deliverables, and financials.
  • Facilitate communication between stakeholders to align project goals and expectations.
  • Contribute to continuous improvement of project management practices and tools.

Qualifications

  • Bachelor’s or Master’s degree in Business Administration, Project Management, or a related field.
  • Minimum of 3 years of experience in project management, preferably in a multi-stakeholder environment.
  • Strong understanding of financial reporting and contract management.
  • Excellent communication and interpersonal skills to engage with diverse teams.
  • Proficiency in project management tools and Microsoft Office Suite.
  • Fluency in English, both written and spoken.

Desired Skills

  • Analytical mindset with attention to detail.
  • Ability to manage multiple projects and deadlines effectively.
  • Problem-solving skills and proactive approach to challenges.
  • Team player with a collaborative spirit.
  • Experience in organizing technical environments such as laboratories is a plus.

What We Offer

  • Competitive salary and benefits package.
  • Opportunities for professional development and career growth.
  • Flexible working arrangements and supportive team environment.
  • Engagement in meaningful projects with societal impact.

Ready to make an impact?

If you are excited about this opportunity and believe your experience aligns with our mission, we’d love to hear from you. Please submit your CV and a brief cover letter outlining your motivation and relevant experience to hr@ombion-cpbt.nl with the subject line “Project Manager Application – [Your Name]”.
We review applications on a rolling basis, so don’t wait, apply today and become part of a team that’s shaping the future through innovation and collaboration.

Contact us:

For more information, please contact us at info@ombion-cpbt.nl

You can also follow us on LinkedIn and subscribe to our quarterly newsletter.

Postal address:

Ombion Centre for Animal-free Biomedical Translation
Yalelaan 62 (Life Sciences Incubator Building)
3584 CM Utrecht

The Netherlands